Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) has engaged IBN to assist with its corporate communications strategy, according to a press release. The move is intended to generate greater awareness for the clinical-stage biopharmaceutical company and its wholly owned subsidiary, MindWave Innovations, which is developing institutional digital asset infrastructure.
MindWave Innovations is building a platform that connects treasury, insurance, tokenized assets, and blockchain ecosystems. The platform combines insured custody, transparent reporting, and technology-driven portfolio management to support risk-aware yield on Bitcoin reserves and institutional participation in the digital asset economy.
Under the agreement, IBN will leverage its investor-focused distribution network, including more than 5,000 syndication outlets, newsletters, social media channels, InvestorWire, and other outreach tools. This broad reach is designed to elevate Apimeds’ profile within the investment community. Investors can view the full press release at https://ibn.fm/PdvmC.
Apimeds Pharmaceuticals US, Inc. is a clinical-stage biopharmaceutical company focused on developing non-opioid, biologic-based therapies for pain management. For more information, visit www.ApimedsUS.com.
MindWave Innovations Inc., a wholly owned subsidiary of Apimeds, is developing enterprise blockchain infrastructure and institutional technology platforms through its MindChain ecosystem. Four ecosystems operate under MindChain: InsurTech through BlockAssure, which is developing a Bermuda-framework platform applying Bitcoin reserves as regulatory capital to support life and property and casualty underwriting; ClimateTech through AQUAE and the ALCI index, measuring, verifying and tokenizing ecosystem services into institutional-grade assets; HealthTech through the Apitox development program; and RWA Tech through Nexus Global Partners, bringing institutional real estate on-chain within a compliance-first, insurance-enhanced framework.
The engagement with IBN comes as Apimeds seeks to distinguish itself in both the biopharmaceutical and digital asset sectors. The latest news and updates relating to APUS are available in the company’s newsroom at https://ibn.fm/APUS.
For readers, this announcement signals Apimeds’ intent to improve market visibility and communicate its dual focus on pain management therapies and blockchain-based financial infrastructure. The involvement of IBN, with its syndication network, could lead to increased investor awareness and potentially greater liquidity for APUS shares. In the broader context, the development of MindWave’s MindChain ecosystem reflects the growing convergence of traditional finance, insurance, and digital assets, which may influence how institutional investors approach Bitcoin reserves and tokenized real-world assets.
MissionIR is a specialized communications platform focused on assisting IR firms with syndicated content to enhance the visibility of private and public companies. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. For more information, visit www.MissionIR.com.
